Phase II Trial of Neratinib and Palbociclib in HER2+ Solid Tumors Initiated
A phase II trial is underway to compare neratinib alone versus its combination with palbociclib in HER2 positive solid tumors.
Therapeutic Area
Therapeutic area intelligence for HER2+ Solid Tumors with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.